Table 4.
Type | Preclinical | Phase 1, route, dose, | Ref |
---|---|---|---|
Live CVD seriesa | + | oral, 109–1010 | 118,140,142 |
Live WRAIR seriesb | + | ongoing | 118,134,138,140,142 |
Live S. typhi Ty21a with Shigella LPS genes | + | 130 | |
Formalin killed cells, trivalent | + | oral, 1010–1011 | 117,125 |
Invaplexd | + | Intranasal | 14,119,125-126 |
LPS conjugates | + | parenteral | 121,125,142 |
Synthetic oligo-saccharides | + | 133,142 | |
Bioglycoconjugatesf | + | parenteral | 132 |
Purified Ipa proteins | + | 139 | |
OMg vesicles | + | 137 |
based on guaBA mutations, multiple serotypes, limited intracellualr replication.
based on virG(icsA) mutations, multiple serotypes, inability to spread intercellularly.
trivalent product with S. sonnei, S. flexneri 2a and 3a.
combination of serotype-specific LPS and conserved antigens IpaB and IpaC proteins, LPS from different serotypes can be substituted.
LPS conjugates with CRM, a non-toxic recombinant variant of diptheria toxin with a single amino acid substitution.
Shigella O-antigen expressed in an E. coli with Campylobacter glycosylation secretion machinery.
OM, outer membrane.